GlassScriptPhysician profile
Neilanjan Nandi
NPI 1710188974
$209,258.13
in general payments reported to CMS, 2019-2025
16 companies · $8,584 in 2025
The $8,584 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78K · 2020: $17K · 2021: $8,411 · 2022: $19K · 2023: $25K · 2024: $52K · 2025: $8,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $62K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $2,993 · Travel and Lodging: $1,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $61,529.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,950.00 |
| Food and Beverage | $2,992.56 |
| Travel and Lodging | $1,508.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $55,085.82 | 2019-2025 | |
| Janssen Biotech, INC. | $46,066.19 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $39,146.95 | 2020-2023 | |
| Eli Lilly and Company | $25,446.61 | 2019-2024 | Omvoh |
| Daiichi Sankyo INC. | $18,300.64 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $8,580.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $8,308.22 | 2019-2025 | Entyvio |
| Genzyme Corporation | $4,174.52 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,500.00 | 2019 | |
| Lilly USA, LLC | $1,310.82 | 2024-2025 | Omvoh |
| Pharmacosmos Therapeutics INC. | $158.62 | 2024 | Monoferric |
| Convatec INC. | $109.61 | 2022 | |
| American Regent | $56.77 | 2020 | |
| Celgene Corporation | $13.36 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neilanjan Nandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.